A Phase 1/2, Open-Label, Dose-Escalationand -Expansion Study of the Bruton TyrosineKinase-Targeted Protein-Degrader BGB-16673 inPatients With B-Cell Malignancies
Contact:
NCT Number:
Protocol:
AAAU5330
Study Status:
Active/Enrolling
Population:
Pediatrics
Phase:
I
The purpose of this study is to look at the safety and tolerability of the study drug, BGB- 16673. Another purpose is to determine the range of BGB-16673 doses that can safely be used. BGB-16673 is an experimental drug. This means that it has not been approved for treatment by the US, the Food and Drug Administration (FDA). This research study is the first time that BGB-16673 will be given to humans and therefore the effects of BGB-16673 on humans are not yet known
Are you Eligible? (Inclusion Criteria)
- Must be 18 years old or older - Must have life expectancy more than 6 months - Must be able to swallow capsules
Specialty Area(s)
Leukemia, Chronic Lymphocytic Leukemia, Lymphoma, Hodgkin's Disease, Immunotherapy
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
